Terms: = Lymphoma AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750
84 results:
1. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
2. Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study.
Munshi L; Dumas G; Rochwerg B; Shoukat F; Detsky M; Fergusson DA; Ferreyro BL; Heffernan P; Herridge M; Magder S; Minden M; Patel R; Qureshi S; Schimmer A; Thyagu S; Wang HT; Mehta S
Intensive Care Med; 2024 Apr; 50(4):561-572. PubMed ID: 38466402
[TBL] [Abstract] [Full Text] [Related]
3. Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Grieve C; Joseph A; Drullinsky P; Zelenetz AD; Hamlin P; Kumar A
Leuk Lymphoma; 2024 Feb; 65(2):235-241. PubMed ID: 38264906
[TBL] [Abstract] [Full Text] [Related]
4. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract] [Full Text] [Related]
5. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic lymphoma Group MCL7 VALERIA trial.
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Blood Adv; 2024 Jan; 8(2):407-415. PubMed ID: 38113470
[TBL] [Abstract] [Full Text] [Related]
6. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract] [Full Text] [Related]
7. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
[TBL] [Abstract] [Full Text] [Related]
8. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
[TBL] [Abstract] [Full Text] [Related]
10. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S; Dubois J; Nasserinejad K; Dobber JA; Mellink C; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken H; Levenga H; Tick LW; Terpstra WE; Tonino SH; Boyer M; Mobasher M; Levin MD; Kater AP;
Lancet Haematol; 2022 Mar; 9(3):e190-e199. PubMed ID: 35240075
[TBL] [Abstract] [Full Text] [Related]
11. Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia.
Krapfl A; McLeod C; Myers R; Venugopal P; Seddon A
J Oncol Pharm Pract; 2022 Dec; 28(8):1898-1901. PubMed ID: 35179064
[TBL] [Abstract] [Full Text] [Related]
12. Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naïve Boy Is Associated With a Novel
Steininger J; Rossmanith R; Geier CB; Leiss-Piller A; Thonhauser L; Weiss S; Hainfellner JA; Freilinger M; Schmidt WM; Eibl MM; Wolf HM
Front Immunol; 2021; 12():747738. PubMed ID: 34987501
[TBL] [Abstract] [Full Text] [Related]
13. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract] [Full Text] [Related]
14. Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US.
Horný M; Shafer PR; Dusetzina SB
JAMA Netw Open; 2021 Dec; 4(12):e2137390. PubMed ID: 34902037
[TBL] [Abstract] [Full Text] [Related]
15. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
[TBL] [Abstract] [Full Text] [Related]
16. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract] [Full Text] [Related]
17. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract] [Full Text] [Related]
18. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract] [Full Text] [Related]
19. A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML).
Ando H; Murakami Y; Eshima K; Ishida T
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1485. PubMed ID: 34173723
[TBL] [Abstract] [Full Text] [Related]
20. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract] [Full Text] [Related]
[Next]
